PAR4激活涉及胞外环3和跨膜残基Thr153
研究利用氢氘交换、计算建模和信号实验解析凝血酶受体PAR4的激活机制,发现配体结合位点由跨膜域TM3和TM7构成,Thr153突变显著降低PAR4信号,胞外环3为门控结构。INVENT联盟GWAS荟萃分析显示,携带PAR4 Leu310等位基因者静脉血栓栓塞相对风险较Pro310等位基因者降低15%(OR 0.85,95%CI 0.77-0.94)。
要点
- PAR4配体结合位点由跨膜域TM3和TM7构成,胞外环3为配体与结合位点相互作用的门控结构。
- Thr153突变显著降低PAR4信号,提示该残基对PAR4激活重要。
- 携带PAR4 Leu310等位基因者静脉血栓栓塞相对风险较Pro310等位基因者降低15%(OR 0.85,95%CI 0.77-0.94)。
核心结论
- 研究揭示了PAR4激活的结构基础,并发现PAR4在静脉血栓栓塞中具有此前未被认识的作用。
研究设计与样本
- 采用氢氘交换、计算建模和信号实验研究PAR4激活机制。
- 利用国际静脉血栓对抗网络(INVENT)联盟多祖先全基因组关联研究(GWAS)荟萃分析,检验第310位多态性与静脉血栓栓塞的关联。
主要发现
- 氢氘交换显示配体结合位点由跨膜域TM3和TM7构成。
- 无偏计算建模预测系链配体Gly48与配体结合位点Thr153相互作用,Thr153突变显著降低PAR4信号。
- 氢氘交换和建模显示胞外环3作为系链配体与配体结合位点相互作用的门控结构。
- 天然序列变异P310L(rs2227376)及两个实验突变S311A和P312L表明,胞外环3中脯氨酸赋予的刚性对PAR4激活必不可少。
- 携带PAR4 Leu310等位基因者静脉血栓栓塞相对风险较Pro310等位基因者降低15%(OR 0.85,95%CI 0.77-0.94)。
关键数值与推荐
- 携带PAR4 Leu310等位基因者静脉血栓栓塞相对风险较Pro310等位基因者降低15%(OR 0.85,95%CI 0.77-0.94)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Protease-activated receptor 4 (PAR4) mediates sustained thrombin signaling in platelets and is required for a stable thrombus. PAR4 is activated by proteolysis of the N terminus to expose a tethered ligand. The structural basis for PAR4 activation and the location of its ligand binding site (LBS) are unknown. Using hydrogen/deuterium exchange (H/D exchange), computational modeling, and signaling studies, we determined the molecular mechanism for tethered ligand-mediated PAR4 activation. H/D exchange identified that the LBS is composed of transmembrane 3 (TM3) domain and TM7. Unbiased computational modeling further predicted an interaction between Gly48 from the tethered ligand and Thr153 from the LBS. Mutating Thr153 significantly decreased PAR4 signaling. H/D exchange and modeling also showed that extracellular loop 3 (ECL3) serves as a gatekeeper for the interaction between the tethered ligand and LBS. A naturally occurring sequence variant (P310L, rs2227376) and 2 experimental mutations (S311A and P312L) determined that the rigidity conferred by prolines in ECL3 are essential for PAR4 activation. Finally, we examined the role of the polymorphism at position 310 in venous thromboembolism (VTE) using the International Network Against Venous Thrombosis (INVENT) consortium multi-ancestry genome-wide association study (GWAS) meta-analysis. Individuals with the PAR4 Leu310 allele had a 15% reduction in relative risk for VTE (odds ratio, 0.85; 95% confidence interval, 0.77-0.94) compared with the Pro310 allele. These data are consistent with our H/D exchange, molecular modeling, and signaling studies. In conclusion, we have uncovered the structural basis for PAR4 activation and identified a previously unrecognized role for PAR4 in VTE.
引用
- Han X, Hofmann L, de la Fuente M, et al. PAR4 activation involves extracellular loop 3 and transmembrane residue Thr153. Blood. 2020. PMID: 32575122. doi:10.1182/blood.2019004634
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。